In addition to IDH1/2, 1p/19q, MGMT, hTERT, TP53, PTEN, EGFR, and ATRX, which were investigated here, we plan to evaluate other genetic markers related to glioma characteristics and prognosis, as well as those recognized as therapeutic and immune targets. The gene discussed is MGMT; the disease is central nervous system cancer.